… therapy for treatment of CRE infected patients across all infections [54]. Currently, TANGO
III is in recruitment phase, comparing meropenem-vaborbactam to piperacillin-tazobactam for …

… infections due to extended-spectrum β-lactamase-producing organisms. … treatment of
extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections…

… In the treatment of infections caused by AmpC-producing Enterobacteriaceae, FEP has
been shown to be a clinically useful carbapenem-sparing alternative. Carbapenems and FEP …

… guidance documents for the treatment of specific infectious processes. Guidance documents
address specific clinical questions for difficult-to-manage infections that are not covered by …

… Due to lack of new antibiotics to treat infections produced by multiresistant bacteria, the
Infectious … Beta‐lactamases producing bacteria, especially carpabenemases, are responsible for …

… the treatment of infections caused … treatment outcomes of bloodstream infections due to
ESBL-producing organisms. We aimed to evaluate treatment outcomes of bloodstream infections …

… cephalosporins or beta-lactam/beta-lactamase inhibitors combination to treat those infections,
… not advocate the use of beta-lactam/beta-lactamase inhibitors combination to treat ESBL …

… intra-abdominal infections. The introduction of these new β-lactam/β-lactamase inhibitor
combinations offers new carbapenem-sparing options for the treatment of ESBL infections. …

… Carbapenems can usually be used to treat infections due to AmpC-producing bacteria, but
carbapenem resistance has been reported in some organisms, since mutations can reduce …

… β-Lactam antibiotics are a mainstay for the treatment of many infections. The addition of β-lactamase
inhibitors enhances their activity against organisms that produce β-lactamases; …